A Phase 2 Randomized Trial of Apremilast in Patients With Atopic Dermatitis.

Eric L Simpson,Shinichi Imafuku,Yves Poulin,Benjamin Ungar,Lisa Zhou,Kunal Malik,Huei-Chi Wen,Hui Xu,Yeriel D Estrada,Xiangyu Peng,Mindy Chen, Nilam Shah,Mayte Suarez-Farinas,Ana B Pavel,Kristine Nograles,Emma Guttman-Yassky

Journal of Investigative Dermatology（2019）

引用 76|浏览19

暂无评分

摘要

APR40 demonstrated modest efficacy and decreased AD-related biomarkers in moderate to severe AD patients. AEs, including cellulitis, were more frequent with APR40, which was discontinued during the trial.

查看译文

关键词

AD,AE,CI,EASI,EoS,ET,PDE4,RT-PCR,sPGA-A,Th

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要